Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.“Comment on ‘international consensus recommendations for the use of prolonged‐infusion β‐lactams endorsed by the American College of Clinical Pharmacy (ACCP), the British Society for Antimicrobial Chemotherapy (BSAC), the Cystic Fibrosis Foundation (CFF), the European Society of Clinical Mi crobiology and Infectious Diseases (ESCMID), the infectious diseases Society of American (IDSA), the Society of Critical Care Medicine (SCCM), and the Society of Infectious Diseases Pharmacists’”
(Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 16, 2024 Category: Drugs & Pharmacology Authors: Carlos Augusto Espinoza Cobeñas Tags: LETTER TO THE EDITOR Source Type: research
Use of bivalirudin after initial heparin management among adult patients on long ‐term venovenous extracorporeal support as a bridge to lung transplant: A case series
AbstractA growing body of evidence supports the use of bivalirudin as an alternative to unfractionated heparin (UFH) for the prevention of thrombotic events in patients on venovenous (VV) extracorporeal membrane oxygenation (ECMO). However, data in patients bridged to lung transplantation are limited. In this case series, we describe the outcomes of six patients who were transitioned from UFH to bivalirudin during their course of VV ECMO support as a bridge to lung transplantation. All six patients were on VV ECMO support until transplant, with a median duration of 73 days. Bivalirudin demonstrated a shorter time to fir...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 3, 2024 Category: Drugs & Pharmacology Authors: Hala Halawi,
Jesse E. Harris,
Ahmad Goodarzi,
Simon Yau,
Jihad G. Youssef,
Mena Botros,
Howard J. Huang Tags: CASE REPORT Source Type: research
Updates in pulmonary drug ‐resistant tuberculosis pharmacotherapy: A focus on BPaL and BPaLM
AbstractDrug-resistant tuberculosis (TB) is a major public health concern and contributes to high morbidity and mortality. New evidence supports the use of shorter duration, all-oral regimens, which represent an encouraging treatment strategy for drug-resistant TB. As a result, the landscape of drug-resistant TB pharmacotherapy has drastically evolved regarding treatment principles and preferred agents. This narrative review focuses on the key updates of drug-resistant TB treatment, including the use of short-duration all-oral regimens, while calling attention to current gaps in knowledge that may be addressed in future ob...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - January 25, 2024 Category: Drugs & Pharmacology Authors: Dana J. Holger,
Ali Althubyani,
Taylor Morrisette,
Nicholas Rebold,
Marylee Tailor Tags: REVIEW Source Type: research
Combination eravacycline therapy for ventilator ‐associated pneumonia due to carbapenem‐resistant Acinetobacter baumannii in patients with COVID‐19: A case series
ConclusionWith limited viable salvage treatment options, combination eravacycline therapy showed favorable microbiological and clinical outcomes in patients with CRAB pneumonia. In light of this, eravacycline could be considered as a potential treatment option when designing CRAB pneumonia salvage therapy regimens. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - January 25, 2024 Category: Drugs & Pharmacology Authors: Melissa N. W. Jackson,
Wenjing Wei,
Norman S. Mang,
Bonnie C. Prokesch,
Jessica K. Ortwine Tags: RESEARCH ARTICLE Source Type: research
Issue Information
(Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - January 20, 2024 Category: Drugs & Pharmacology Tags: ISSUE INFORMATION Source Type: research
Identification of risk factors associated with acute kidney injury in patients taking sodium ‐glucose cotransporter‐2 inhibitors
ConclusionsThe transient eGFR decline with SGLT2 inhibitor initiation should be expected and is generally not an indication to discontinue therapy. Future initiatives should be directed at increasing knowledge of monitoring recommendations for these agents. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - January 12, 2024 Category: Drugs & Pharmacology Authors: Christie Schumacher,
Amanda Chorpash,
Charlotte Bolch,
Kellye Eagan,
Sara Nimer,
Elizabeth Van Dril Tags: RESEARCH ARTICLE Source Type: research
Real world study on elexacaftor ‐tezacaftor‐ivacaftor impact on cholesterol levels in adults with cystic fibrosis
ConclusionIn this real-world cohort of PwCF, cholesterol parameters increased after initiation with ETI therapy. Further consideration may need to be given for PwCF in regards to screening for cardiometabolic risk factors as PwCF age as well as the potential need for cholesterol-lowering therapies. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - January 12, 2024 Category: Drugs & Pharmacology Authors: Kevin Lonabaugh,
Galvin Li,
Rhonda List,
Reyna Huang,
Amber James,
Andrew Barros,
Lindsay Somerville,
Dana Albon Tags: RESEARCH ARTICLE Source Type: research
Correction to “International consensus recommendations for the use of prolonged‐infusion beta‐lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseas es, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists”
(Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - January 12, 2024 Category: Drugs & Pharmacology Tags: ERRATUM Source Type: research
Multicenter study evaluating target attainment of anti ‐Factor Xa levels using various enoxaparin prophylactic dosing practices in adult trauma patients
ConclusionsAn EBV-based dosing strategy was associated with higher odds of achieving anti-Xa level within target range for enoxaparin VTE prophylaxis compared to BMI-based dosing and may be a preferred method for VTE prophylaxis in adult trauma patients. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - January 8, 2024 Category: Drugs & Pharmacology Authors: Tyler Chanas,
Gabrielle Gibson,
Elizabeth Langenstroer,
David J. Herrmann,
Thomas W. Carver,
Kaitlin Alexander,
Sai Ho Jason Chui,
Lisa Rein,
Michael Ha,
Kaylee M. Maynard,
Kristen Bamberg,
Mary O'Keefe,
Marisa O'Brien,
Mariela Cardona Gonzal Tags: RESEARCH ARTICLE Source Type: research
Is reversal of anticoagulants necessary in neurologically intact traumatic intracranial hemorrhage?
ConclusionThis study found no difference in hospital outcomes between patients with minor traumatic ICH on oral anticoagulants who were neurologically intact that were reversed versus those who were not reversed. Further studies should continue to define the subset of traumatic ICH patients who may not require reversal of anticoagulation. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - January 2, 2024 Category: Drugs & Pharmacology Authors: Kelly Powell,
William Curtiss III,
Erin Sadek,
Jason Hecht Tags: RESEARCH ARTICLE Source Type: research
Multicenter study evaluating target attainment of anti ‐Factor Xa levels using various enoxaparin prophylactic dosing practices in adult trauma patients
This study compared BMI-, TBW-, EBV-based, and hybrid enoxaparin dosing strategies at achieving target prophylactic anti-Factor Xa (anti-Xa) levels in trauma patients.This was a multicenter, retrospective review of adult trauma patients who received enoxaparin twice daily for VTE prophylaxis and had at least one appropriately timed anti-Xa level (collected 3 to 6 hours after the previous dose after three consecutive doses) from January 2017 through December 2020. Patients were excluded if the hospital-specific dosing protocol was not followed or if they had thermal burns with> 20% body surface area involvement. The p...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - December 27, 2023 Category: Drugs & Pharmacology Authors: Tyler Chanas,
Gabrielle Gibson,
Elizabeth Langenstroer,
David J. Herrmann,
Thomas W. Carver,
Kaitlin Alexander,
Sai Ho Jason Chui,
Lisa Rein,
Michael Ha,
Kaylee M. Maynard,
Kristen Bamberg,
Mary O ’Keefe,
Marisa O’Brien,
Mariela Cardona G Tags: RESEARCH ARTICLE Source Type: research
